These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38908022)

  • 1. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
    Zhu X; Chan E; Turski ML; Mendez CE; Hsu SC; Kumar V; Shipp C; Jindal T; Chang K; Onodera C; Devine WP; Grenert JP; Stohr BA; Ding CC; Stachler MD; Quigley DA; Feng FY; Chu CE; Porten SP; Chou J; Friedlander TW; Koshkin VS
    Oncologist; 2024 Aug; 29(8):e1094-e1097. PubMed ID: 38908022
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sakai K; Maeda S; Saeki K; Yoshitake R; Goto-Koshino Y; Nakagawa T; Nishimura R; Yonezawa T; Matsuki N
    Vet Pathol; 2020 Jan; 57(1):56-65. PubMed ID: 31640537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.
    Eriksson P; Sjödahl G; Chebil G; Liedberg F; Höglund M
    Oncotarget; 2017 Jul; 8(30):48905-48914. PubMed ID: 28388586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
    Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
    Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
    Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 as a target in invasive urothelial carcinoma.
    Bellmunt J; Werner L; Bamias A; Fay AP; Park RS; Riester M; Selvarajah S; Barletta JA; Berman DM; de Muga S; Salido M; Gallardo E; Rojo F; Guancial EA; Bambury R; Mullane SA; Choueiri TK; Loda M; Stack E; Rosenberg J
    Cancer Med; 2015 Jun; 4(6):844-52. PubMed ID: 25720673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O; Ligon AH; Hornick JL; Sholl LM
    Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience.
    Rizzo A; Mollica V; Giunchi F; Dall'Olio FG; Rosellini M; Marchetti A; Franceschini T; Schiavina R; Brunocilla E; Fiorentino M; Ardizzoni A; Massari F
    Pathol Res Pract; 2021 Apr; 220():153410. PubMed ID: 33765474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
    Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
    Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.
    Sasaki Y; Sasaki T; Kawai T; Morikawa T; Matsusaka K; Kunita A; Kume H; Aoki I; Homma Y; Fukayama M
    Int J Clin Exp Pathol; 2014; 7(2):699-708. PubMed ID: 24551292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
    Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
    BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
    Ichikawa H; Usui K; Aizawa M; Shimada Y; Muneoka Y; Kano Y; Sugai M; Moro K; Hirose Y; Miura K; Sakata J; Yabusaki H; Nakagawa S; Kawasaki T; Umezu H; Okuda S; Wakai T
    BMC Cancer; 2024 Jun; 24(1):719. PubMed ID: 38862927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
    Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2).
    Hechtman JF; Liu W; Sadowska J; Zhen L; Borsu L; Arcila ME; Won HH; Shah RH; Berger MF; Vakiani E; Shia J; Klimstra DS
    Mod Pathol; 2015 Aug; 28(8):1123-9. PubMed ID: 25975284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.
    Yorozu T; Sato S; Kimura T; Iwatani K; Onuma H; Yanagisawa T; Miki J; Egawa S; Ikegami M; Takahashi H
    Clin Genitourin Cancer; 2020 Aug; 18(4):e443-e449. PubMed ID: 31983622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
    Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
    Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
    Zheng L; Chen H; Zhao J; Roy-Chowdhuri S; Kamat AM; Alhalabi O; Gao J; Siefker-Radtke A; Hansel DE; Czerniak B; Guo CC
    Hum Pathol; 2024 Jun; 148():1-6. PubMed ID: 38679207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.